Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardant Health's revenue for the
three
months ended in Mar. 2026 was MXN5,440 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN19,739 Mil.
Guardant Health's Revenue per Share for the
three
months ended in Mar. 2026 was MXN41.44.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN154.98.
During the past 12 months, the average Revenue per Share Growth Rate of Guardant Health was 35.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 21.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, Guardant Health's highest 3-Year average Revenue per Share Growth Rate was 87.80% per year. The lowest was 7.40% per year. And the median was 21.20% per year.
Guardant Health (MEX:GH) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Guardant Health Revenue Related Terms
Guardant Health Revenue Historical Data
* Premium members only.
The historical data trend for Guardant Health's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Revenue vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Revenue distribution charts can be found below:
* The bar in red indicates where Guardant Health's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN19,739 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (MEX:GH) has a Revenue of MXN19,739 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Guardant Health and its competitors.
Is Guardant Health's Revenue too high?
Guardant Health's current Revenue is MXN19,739 Mil. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Revenue compare to LH and DGX?
Guardant Health's Revenue of MXN19,739 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Diagnostics & Research company?
A good Revenue depends on the Medical Diagnostics & Research industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Guardant Health and its competitors. Guardant Health's current Revenue is MXN19,739 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN1,355.56, compared to a current price of MXN2,590.00 — trading 91.1% above its estimated fair value. The current Revenue is MXN19,739 Mil. Guardant Health's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current Revenue is MXN19,739 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 91.1% above its estimated GF Value™ of MXN1,355.56.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for MEX:GH:
Revenue: MXN19,739 Mil
GF Value™: MXN1,355.56 vs. price of MXN2,590.00 (91.1% above fair value)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
